Plain-English translation of NCT07337785 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called RD06-05, which uses specially modified immune cells (CAR-T cells) to help treat autoimmune diseases that affect the nervous system. These cells are designed to target and calm down the parts of your immune system that are attacking your nerves and brain. Researchers want to learn whether this treatment is safe and whether it can help improve symptoms in people with conditions like multiple sclerosis, myasthenia gravis, and other autoimmune neurological diseases.
People with autoimmune neurological diseases often do not respond well to current treatments, or their symptoms keep getting worse despite medication. This trial exists to explore whether this new type of cell-based therapy could offer hope to patients whose conditions haven't improved with standard treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would first receive two rounds of chemotherapy over three days to prepare your body for the new treatment. Then you would receive a single infusion of the modified immune cells (RD06-05) through an IV. After that, you would return for regular visits so doctors can monitor how you're doing, check for side effects, and measure whether the treatment is helping your symptoms. The trial will likely follow you for several months to track both safety and effectiveness.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China